Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Leukemia|May 10, 2023
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse modelMelanie Langhammer, Julia Schöpf, Timo Jaquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Molecular Oncology|October 15, 2021
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancerSilvia Waldeck, Jan Mitschke, Sebastian Wiesemann, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Leukemia|May 10, 2023
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse modelMelanie Langhammer, Julia Schöpf, Timo Jaquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Molecular Oncology|October 15, 2021
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancerSilvia Waldeck, Jan Mitschke, Sebastian Wiesemann, et al.
Pageof 10